|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128, 928; DataStar PHAR)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
top
| A |
ALIMENTARY/METABOLIC PRODUCTS |
| A1A |
STOMATOLOGICAL
Products for
use in the anterior part of the mouth ie. periodontium (teeth), gingivae
(gums), tongue, palate etc, but not the throat. It includes treatments for
gingivitis (inflammation of the gums), pyorrhea (periodontitis) and oral
ulcers. Compounds in development include antibacterial formulations, inhibitors
of the immune system, and bone morphogenetic protein-2 and osteogenic protein. |
| A2A |
ANTACID/ANTIFLATULENT
Generally
simple basic compounds that neutralize excess acidity in the stomach for the
treatment of indigestion (dyspepsia). Combinations of the antacids aluminium
and magnesium are in development. |
| A2B |
ANTIULCER
Products for the
treatment of duodenal, gastric, peptic ulcers and ulcers caused by Zollinger-Ellison
syndrome. Includes prostaglandins, H2-antagonists, proton pump (H+/K+-ATPase
inhibitors) and phosphodiesterase inhibitors. |
| A3 |
ANTISPASMODIC
Products for
the treatment of symptomatic diffuse oesophageal spasm, which may cause chest
pain (oesophagitis reflux, heartburn) and gastro-oesophageal reflux. Drugs
undergoing investigation include selective antimuscarinic agents and atypical b3-agonists. |
| A4A |
ANTIEMETIC
Products for
emesis, nausea and vomiting, including improved 5-HT3 antagonists, cannabinoids,
selective vasopressin V1 receptor antagonists, as well as dopamine D2,
tachykinin and 5-HT4 antagonists. |
| A4B |
GASTROPROKINETIC
Products for
delayed emptying of the contents of the stomach due to gastric hypomotility,
which can lead to several gastrointestinal disorders, and compounds for
pancreatic and biliary dyskinesias. Drug strategies include dopamine
antagonistic activity, the indirect enhancement of acetylcholine release, k opioid agonists and 5-HT4 agonists. Cholecystokinin
(CCK) antagonists for biliary dyskinesias. |
| A5B |
HEPATOPROTECTIVE
Products for
jaundice (hyperbilirubinaemia), liver cirrhosis, liver fibrosis and hepatic
(portal-systemic) encephalopathy. Also includes products that protect against
the degradation of liver tissues by by-products of detoxification and liver
metabolism and by other liver-damaging diseases. Enzyme inducers of bilirubin
oxidase, immunosuppressants and inhibitors of hydroxylases and transaminases
are being investigated. Also includes compounds for the treatment of hepatic
dysfunction and hepatic insufficiency. |
| A5D |
GALLSTONE THERAPY
Products for
use in gallstones (biliary calculi) therapy include bile salt re-uptake
inhibitors. |
| A6 |
LAXATIVE
Laxatives
promote defaecation and are indicated for the treatment of constipation.
Formulations of existing laxatives, and opioid antagonists are being
investigated. |
| A7 |
ANTIDIARRHOEAL
Products in
development for diarrhoea - the excessive faecal loss of fluid and electrolytes
- include specific opioid agonists (both m
and d receptors), enkephalinase inhibitors,
somatostatin analogues and chelating agents. |
| A8A3 |
ANORECTIC/ANTIOBESITY
Most
anorectics suppress appetite via an effect on the central nervous system. They
affect the dopamine, opioid, norepinephrine and 5-HT-mediated pathways of
appetite control. Products under investigation include 5-HT reuptake
inhibitors, cholecystokinin agonists, as well as b3-adrenoceptor
agonists which stimulate thermogenesis and also b3-adrenoceptor
antagonists which suppress endogenous glucose production. |
| A9 |
DIGESTIVE
Digestants
promote the process of digestion in the gastrointestinal tract where there is a
lack of one or more specific substances that are involved in the digestion of
food, including formulations of pancreatin with high lipase content. |
| A10B |
ANTIDIABETIC
Products for
the treatment of diabetes mellitus include recombinant human insulin,
encapsulated insulin-producing cells, and hypoglycaemic agents, such as a2-adrenoceptor antagonists, somatomedins
(somatomedin-C, insulin-like growth factor-1; somatomedin-A, IGF-2) and a-glucosidase inhibitors. |
| A10C |
SYMPTOMATIC
ANTIDIABETIC
Products for
the treatment of secondary complications of diabetes, such as glycosuria,
polydypsia, ketosis, microangiopathy, nephropathy, retinopathy and neuropathy
include aldose reductase inhibitors glycosylation inhibitors, ciliary
neurotrophic factors and regeneration of nerve cells. |
| A11A |
NUTRITIONAL
SUPPLEMENT
Mineral
supplements, preparations of amino acids or trace elements, parenteral
nutrition preparations and vitamin preparations for a variety of conditions are
being developed. |
| A14 |
ANABOLIC
Anabolics are
primarily of use in the rapid recovery from cachexia and protein-wasting
disorders. Products include those which reduce plasma tumour necrosis factor levels. |
| A15 |
APPETITE
STIMULANT
Products which
stimulate appetite are of use in anorexia (loss of appetite, not the mental
disorder, anorexia nervosa (see Antineurosis (N5D)). Compounds in development
include inhibitors of gastrin release, cannabinoids, and cholecystokinin (CCK)
antagonists. |
| A16 |
GI
INFLAMMATORY/BOWEL DISORDERS
Includes
compounds for the treatment of colitis, ulcerative colitis, Crohn's disease,
inflammatory bowel disease, irritable bowel syndrome, pancreatitis, gastritis,
gasteroenteritis, gastroparesis, GI motility dysfunction and short bowel
syndrome. |
| A17 |
METABOLIC
AND ENZYME DISORDERS
Includes products
for the treatment of Coeliac disease, Fabry's disease, Gaucher's disease, homocystinuria,
hyperammonaemia, hyperbilirubinaemia, hyperkalaemia, hyperoxaluria, hyperphosphataemia,
hyperprolactinaemia, hyponatraemia, acidosis, cystinosis, Pompe's disease,
Tay-Sachs disease, sucrase isomaltase deficiency and Wilson's disease. |
| A18Z |
ALIMENTARY/METABOLIC
GENERAL
Anything that
cannot be placed in any of the other alimentary categories. Includes
choleretics which stimulate the secretion of bile. |
top
| B |
BLOOD AND CLOTTING PRODUCTS |
| B1A |
ANTICOAGULANT
Products being
developed that prevent the formation of blood clots include inhibitors of
Factor VIIa and Factor Xa, a1-antitrypsins, low molecular weight
heparins, and recombinant versions of hirudin. |
| B1B1 |
FIBRINOLYTIC
Fibrinolysis
is the process by which blood clots are dissolved in the body. Products that
are being developed include anistreplase, recombinant versions of urokinase and
pro-urokinase (PUK), and second-generation tPA products (tPA-2). |
| B1B9 |
ANTITHROMBOTIC
An
antithrombotic prevents the aggregation of platelets (thrombocytes). Thrombin
inhibitors in development include purified forms of the fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and recombinant
versions of antithrombin III. Inhibitors of platelet aggregation include
calcium antagonists, PAF-antagonists, prostaglandin (PG) derivatives and
glycoprotein (GPIIb/IIIa) antagonists. |
| B2A |
ANTIFIBRINOLYTIC
Antifibrinolytics
are used to treat disorders resulting from overactivity of the fibrinolytic
system and in cases of haemorrhage resulting from hyperfibrinolysis.
Recombinant plasminogen activator inhibitor-1 (rPAI-1) is being investigated. |
| B2B |
HAEMOSTATIC
Haemostatic
compounds speed up the time it takes for bleeding to stop. Purified and
recombinant versions of Factor VIII and Factor IX are being developed as are
Factor VIII fragments, Factor VIIa, Factor XIIa and Tissue Factor. Other
haemostatics in development include recombinant kallikrein antagonists and
human polymorphonuclear (PMN) elastase inhibitors. |
| B3C1 |
ANTISICKLING
Products in
development for sickle cell anaemia include stabilizers of the oxy-conformation
of haemoglobin as well as polyethylene glycol (PEG)-conjugated forms of
haemoglobin. |
| B3C9 |
ANTIANAEMIC
Products for
the treatment or prevention of anaemia (such as iron-deficiency anaemia,
aplastic (hypoplastic) anaemia, pernicious anaemia and thalassaemia) include
iron formulations, interleukins-3, 4 and 6, granulocyte macrophage colony
stimulating factor, cAMP phosphodiesterase inhibitors and formulations of
vitamin B12. |
| B5A1 |
PLASMA
SUBSTITUTE
New
developments for plasma substitutes are focusing on suitable oxygen-carrying
fluids and include perfluro chemicals and inulin (polyfructan) combined with
haemoglobin. |
| B5A2 |
BLOOD
FRACTION
Various blood
clotting factors are under investigation for the treatment of haemophilias and
other diseases. |
| B6A |
SEPTIC
SHOCK TREATMENT
Products under
investigation for systemic inflammatory response syndrome (SIRS), sepsis,
severe sepsis, septic shock and sepsis-induced hypotension include tumour
necrosis factor (TNF) and interleukin-1 (IL-1) inhibitors, various monoclonal
antibodies fragments of Bactericidal Permeability Increasing (BPI) protein and
nitric oxide inhibitors. |
| B7Z |
HAEMATOLOGICAL
This section
includes products with a haematological action which is either unknown to
Pharmaprojects, or is not specified by any of the other "B"
categories. Products for the treatment of thrombocytopenia. Products being
investigated include interleukin-6 (B-cell stimulating factor-2), and fusion
molecules of granulocyte macrophage colony stimulating factor (GM-CSF) with interleukin-3. |
Last modified on 15 Apr 2005.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928; DataStar PHAR) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home